Combination of 3D printing technologies and compressed tablets for preparation of riboflavin floating tablet-in-device (TiD) systems

Fu, Junhui; Yin, Huiming; Yu, Xiang; Xie, Conghua; Jiang, Heliu; Jin, Yiguang; Sheng, Fugeng

doi:10.1016/j.ijpharm.2018.08.011

Cited by 102 publications

(60 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PLLA has a melting temperature of around 175 • C, a T g of 60-65 • C, and a mechanical strength of 4.8 GPa; whereas, PDLLA has a slightly lower T g of 55-60 • C and a mechanical strength of 1.9 GPa [94]. PLA can last up to three hours in acid, which is more suited to drugs that require a delayed release [99].…”

Section: Polylactic Acid (Pla)mentioning

confidence: 99%

See 1 more Smart Citation

Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective

et al. 2020

View full text Add to dashboard Cite

Three dimensional (3D) printing as an advanced manufacturing technology is progressing to be established in the pharmaceutical industry to overcome the traditional manufacturing regime of 'one size fits for all'. Using 3D printing, it is possible to design and develop complex dosage forms that can be suitable for tuning drug release. Polymers are the key materials that are necessary for 3D printing. Among all 3D printing processes, extrusion-based (both fused deposition modeling (FDM) and pressure-assisted microsyringe (PAM)) 3D printing is well researched for pharmaceutical manufacturing. It is important to understand which polymers are suitable for extrusion-based 3D printing of pharmaceuticals and how their properties, as well as the behavior of polymer–active pharmaceutical ingredient (API) combinations, impact the printing process. Especially, understanding the rheology of the polymer and API–polymer mixtures is necessary for successful 3D printing of dosage forms or printed structures. This review has summarized a holistic materials–process perspective for polymers on extrusion-based 3D printing. The main focus herein will be both FDM and PAM 3D printing processes. It elaborates the discussion on the comparison of 3D printing with the traditional direct compression process, the necessity of rheology, and the characterization techniques required for the printed structure, drug, and excipients. The current technological challenges, regulatory aspects, and the direction toward which the technology is moving, especially for personalized pharmaceuticals and multi-drug printing, are also briefly discussed.

show abstract

Section: Polylactic Acid (Pla)mentioning

confidence: 99%

“…It is widely used in FDM [102]. PVA is suitable for immediate release tablets as it dissolves more readily in hydrochloric acid [99]. However, controlled release can be achieved using PVA if the capsule is designed as a series of concentric circles to delay release [103].…”

Section: Polyvinyl Alcohol (Pva)mentioning

confidence: 99%

Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective

et al. 2020

View full text Add to dashboard Cite

show abstract

“…At the same time, this approach provides the possibility to adjust and tightly regulate the targeted delivery and the release mechanism of the API. Floating systems have been developed by combining FFF and tablet compression, exhibiting controlled drug release [8][9][10]. Furthermore, a floating device was designed and printed by FFF, aiming to host a commercially available drug-loaded capsule [11].…”

Section: Filled Formulationsmentioning

confidence: 99%

Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology

Eleftheriadis

Katsiotis

Genina

et al. 2020

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

The potential of fused filament fabrication (FFF) for the administration of active pharmaceutical compounds is a recent approach to develop complex and custom-made drug delivery systems (DDSs). However, the FFF technology is characterized by certain limitations, which are associated with the nature of the process, i.e., the required mechanical properties of the feedstock, as well as the thermal stability of the incorporated polymers, excipients and active compounds. Thus, hybrid DDSs have been recently introduced, to overcome these boundaries. The concept of these systems is defined by the effective coupling of FFF with conventional manufacturing technologies, as a novel pathway to expand the available pool of raw materials and pharmaceutical applications of FFF.

show abstract

“…[12][13][14][15][16] One shortcoming of photopolymerization-based 3D techniques is production of "dead" materials, due to the use of nonliving free radical polymerization. 17,18 Although 3D printed shape memory polymers are capable of evolving their shape and property with time in response to an external stimulus, [19][20][21][22][23][24][25][26][27] directly linking new polymers covalently from the surface of 3D printouts has not been achievable.…”

Section: Introductionmentioning

confidence: 99%

PET-RAFT Facilitated 3D Printing of Polymeric Materials

Bagheri

Bainbridge²,

Engel³

et al. 2019

Preprint

View full text Add to dashboard Cite

Photopolymerization-based 3D printing process is typically conducted using nonliving free radical polymerization, which leads to fabrication of immutable materials. An alternative 3D printing of polymeric materials using trithiocarbonate (TTC) reversible addition-fragmentation chain transfer (RAFT) agents has always been a challenge for material and polymer scientists. Herein we report the first 3D printing of RAFT-based formulations that can be conducted fully open to air using standard digital light processing (DLP) 3D printer and under mild conditions of visible light at blue (λ max = 483 nm, 4.16 mW/cm2) or green (λ max = 532 nm, 0.48 mW/cm2) wavelength. Our approach is based on activation of TTC RAFT agents using eosin Y (EY) as a photoinduced electron-transfer (PET) catalyst in the presence of a reducing agent (tertiary amine), which facilitated oxygen tolerant 3D printing process via a reductive PET initiation mechanism. Re-activation of the TTCs present within the polymer networks enables post-printing monomer insertion into the outer layers of an already printed dormant object under second RAFT process, which provides a new pathway to design a more complex 3D printing. To our best knowledge, this is the first example of open-to-air PET-RAFT facilitated 3D printing of polymeric materials. We believe that our strategy is a significant step forward in the field of 3D printing.

show abstract

Combination of 3D printing technologies and compressed tablets for preparation of riboflavin floating tablet-in-device (TiD) systems

Cited by 102 publications

References 30 publications

Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective

Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective

Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology

PET-RAFT Facilitated 3D Printing of Polymeric Materials

Contact Info

Product

Resources

About